الفهرس 
Hepatocellular CarcinomaOnly 14 pages are availabe for public view
 |  | from | 186 |  |  |
| | | from | 186 | | |
Abstract
Nanoparticles allow early detection and delivery of chemotherapeutic drugs to tumor site. This study aimed to assess therapeutic role of dumbbell-like nanoparticles conjugated monoclonal antibodies against VEGF and CD90 in hepatocellular carcinoma (HCC) experimental model. HCC induced mice were divided into; pathological control, mAbs-conjugated nanoparticles, non-conjugated nanoparticles and Avastin. Serum samples were collected and analyzed for AFP, caspases-3, VEGF-A, ALT and AST. Liver sections of sacrificed animals were analyzed. There were significant differences between mAbs-conjugated nanoparticles and Avastin in comparison to pathological control; both achieved significant decrease in all serum parameters, but mAbs-conjugated nanoparticles group had more potent improvement effect compared to Avastin group. MAbs-conjugated nanoparticles group showed the best improvement in liver architecture. In conclusion, dumbbell-like nanoparticles conjugated to CD90 and Avastin is a novel therapeutic tool for HCC to target cancer stem cells and endothelial cells in the niche of the tumor.